About Sware
Sware is a company based in Chelsea (United States) founded in 2015 by Kosal Keo. Sware has raised $24.37 million across 4 funding rounds from investors including First Analysis, LRVHealth and New Stack Ventures. Sware offers products and services including Res_Q and GxPNext. Sware operates in a competitive market with competitors including RIMSYS, ValGenesis, Virtify, 3Aware and Essenvia, among others.
- Total Equity Funding$24.37 M (USD)
in 4 rounds
- Latest Funding Round$6.02 M (USD), Series B
Apr 17, 2024
- InvestorsFirst Analysis
& 4 more
Products & Services of Sware
Sware offers a comprehensive portfolio of products and services, including Res_Q and GxPNext.
Automates GxP validation processes to reduce costs and ensure compliance
Manages GxP requirements for life sciences through unified platforms
Funding Insights of Sware
Sware has successfully raised a total of $24.37M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $6.02 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.4M
- Total Rounds 4
- Last Round Series B — $6.0M
- First Round $150,000
(15 Jun 2020)
- Investors Count 5
All 4 funding rounds of Sware with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 17 Apr 2024 | $6.0M | Series B | – | First Analysis | |
| 09 Feb 2022 | $15.0M | Series A | – | – | |
| 26 May 2021 | $3.2M | Series A | – | – | – |
| 15 Jun 2020 | $150,000 | Seed | – | – |
5 investors in total: 5 institutional.
Investors in Sware
Sware has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include First Analysis, LRVHealth and New Stack Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and transaction advisory services for B2B tech companies. | – | firstanalysis.com | - | |
Early stage venture capital firm investing in the US | – | lrvhealth.com | Boston, United States | |
Early-stage venture capital investments are made in innovative startups. | 2014 | newstack.com | Chicago, United States | |
Investment firm scaling software and technology companies from early to late stages. | – | insightpartners.com | - | |
- | – | jsf.co | - |
Investor details for Sware
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sware
2 people are tracked at Sware (2 in leadership).
| Name | Role | Group |
|---|---|---|
Kosal Keo | Founder | Leadership |
Bryan Ennis | CEO | Leadership |
Complete people profiles for Sware
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sware
3 dated milestones of Sware across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Sware is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Series B, of $6.0M.
Competitors of Sware
Sware operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RIMSYS, ValGenesis, Virtify, 3Aware and Essenvia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rimsys.io | 2017 | Pittsburgh, United States | $25.8M | 31 | Medical device regulatory management software is provided for healthcare organizations. | |
| valgenesis.com | 2005 | Fremont, United States | $24.0M | 431 | Validation software is provided for life sciences companies. | |
| virtify.com | 2004 | Cambridge, United States | $23.5M | 23 | Delivers content and compliance management software solutions. | |
| 3aware.ai | 2022 | Indianapolis, United States | $2.1M | – | Provider of real-world evidence platform for MedTech device safety and performance | |
| essenvia.com | 2018 | Los Angeles, United States | $5.5M | – | Software for medical device pre- and post-market workflows is provided. | |
| netregulus.com | 1999 | Boston, United States | $13.4M | – | Quality and regulatory data management solutions for life sciences industry | |
| targethealth.com | 1993 | New York, United States | – | 85 | Full-service clinical research organization software and services are provided. | |
| samarindrms.com | 1987 | Deeside, United Kingdom | – | 436 | Software solutions are provided for life sciences and other sectors. |
Detailed competitors of Sware
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Sware
10 companies that operate in the same segment as Sware (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sware
Sware was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Sware is headquartered in Chelsea, United States. It is registered at Chelsea, Massachusetts, United States.
Bryan Ennis is the current CEO of Sware.
Sware is a funded company, having raised a total of $24.37M across 4 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Jun 15, 2020.
A platform for validation automation in regulated systems was established in 2015 and is based in Chelsea, United States. Operations focus on the compliance technology sector, where the Res_Q system is utilized for lifecycle management and workflow automation. Compliance with regulated technology solutions is managed through these tools, supporting industries requiring strict validation protocols. Leadership includes a founder and CEO guiding development.
Sware's top competitors include RIMSYS, ValGenesis and 3Aware.
Sware offers Res_Q and GxPNext.
Sware has 5 investors. Key investors include First Analysis, LRVHealth, New Stack Ventures, Insight Partners, and Jumpstart Foundry.
Sware operates through Sware, Inc..